SPPAM
CAI

Summit Partners Public Asset Management’s Caris Life Sciences CAI Stock Holding History

Summit Partners Public Asset Management’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-296,000
Closed -$7.91M – 233
2025
Q2 		$7.91M Buy
+296,000
New +$7.98M 0.2% 101

Other funds holding CAI

SSP
Sixth Street Partners Dallas, Texas $711M AUM 9.3% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SLG
Silver Lake Group Menlo Park, California $3.68B AUM 7.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Summit Partners Public Asset Management's CAI Position: Q3 2025 in Review

Summit Partners Public Asset Management sold out of Caris Life Sciences (CAI) in Q3 2025, closing a stake of 296,000 shares — an estimated $7.91M sold.

Summit Partners Public Asset Management first reported a position in CAI in Q2 2025 and held it in 1 quarter. The position peaked at $7.91M in Q2 2025. 138 funds tracked by Wall St. Rank hold CAI as of Q3 2025.

  • Summit Partners Public Asset Management reported no remaining Caris Life Sciences position as of Q3 2025 after selling out during the quarter.
  • Summit Partners Public Asset Management sold 296,000 Caris Life Sciences shares in Q3 2025, an estimated $7.91M.
  • Summit Partners Public Asset Management first reported a position in Caris Life Sciences in Q2 2025 and held it in 1 quarter.
  • Summit Partners Public Asset Management's Caris Life Sciences position peaked at $7.91M in Q2 2025.
  • 138 funds tracked by Wall St. Rank held Caris Life Sciences as of Q3 2025.

Based on Summit Partners Public Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.